The therapeutic guideline of HES depends on numerous factors, including the clinical presentation, laboratory findings, and the variant of gene mutation (FIP1L1/PDGFRA mutation), which is HES with myeloproliferative features. The gene discussed is FIP1L1; the disease is hypereosinophilic syndrome.